RIYADH: The Saudi Food and Drug Authority will organize the Generic Drugs Conference 2025 under the title “Empowering Local Pharmaceutical Manufacturing: The Future of Generic Drugs in Saudi Arabia” on Dec. 30 in Riyadh.
The conference aim is to build a resilient, sustainable pharmaceutical sector that supports public health, according to a press release issued by the Saudi food safety watchdog.
The conference will be a unique platform bringing together healthcare providers, regulatory experts, academics, investors, and major pharmaceutical companies to foster open dialogue, share global best practices, and align efforts toward strengthening the generic drug sector in Saudi Arabia.
Bringing together a distinguished group of experts, leaders, regulators, healthcare professionals and pharmaceutical industry leaders, the conference will discuss the latest developments, challenges, and opportunities in the field of generic medicines.
With discussion sessions, interactive dialogues and numerous networking opportunities, the conference opens new horizons to enhance collaboration, innovation, and sustainable growth in the generic medicines sector, supporting improved access to medicines and raising their quality.
The conference agenda is designed to address strategic themes, including national efforts to enhance drug security; investment and regulatory enablers for generic drug manufacturing; pharmaceutical research and development and formulation challenges; pricing, reimbursement, and market access policies; and supply chain resilience and good manufacturing practice compliance, all aimed at strengthening public confidence in generics.
The conference, designed for professionals and stakeholders involved in the development, regulation, manufacturing, and distribution of generic and biosimilar medicines, comes at a pivotal time in Saudi Arabia’s healthcare and pharmaceutical sectors.
With Saudi Vision 2030 driving economic diversification and healthcare transformation, the local pharmaceutical industry is a cornerstone of national drug security, public health sustainability, and economic growth.
